Developing a new drug costs $2.6 billion and takes 10 to 15 years. Those numbers are well known. What is less discussed — and what I have observed repeatedly across 25 years of pharma R&D — is this: 12 to 17 months of that timeline is spent waiting for governance meetings.
Not waiting for experiments to complete. Not waiting for patient recruitment. Not waiting for regulatory review. Just waiting for committees to meet.
"The Project Team finishes their assessment on a Tuesday. The Stage Gate Committee meets monthly, on the first Monday. You just lost three to four weeks — regardless of the decision's complexity."
I have seen this pattern at every level of pharma R&D — from early-stage biotechs to global top-10 organisations. A team misses a governance window by days and waits weeks for the next one. Or the agenda is too full and a critical go/no-go decision gets bumped to the following month. The calendar becomes the bottleneck, not the science.
The Hidden Cost of Decision Latency
The pharmaceutical industry has a concept it rarely measures with the rigour it deserves: Decision Latency — the time between when a decision is ready to be made and when it is actually made.
Based on transformation work I have led across multiple organisations and industry benchmarking, the gap between traditional and best-in-class practice is stark:
| Metric | Traditional Approach | Best-in-Class |
|---|---|---|
| Wait time per gate | 3–4 weeks | Few days to 1 week |
| Decision Latency Index | 2–3 weeks | 3–5 days |
| Cumulative impact (IND to approval) | 12–17+ months | Under 6 months |
The compounding effect is what makes this so damaging. A three-week delay at each of five governance points across a development programme doesn't cost fifteen weeks. It costs months of downstream delay — to the next trial, to regulatory submission, to patients.
Leading Companies Are Already Moving
The organisations pulling ahead have not simply added more governance capacity. They have fundamentally rethought when, how, and who makes decisions.
During COVID-19 vaccine development, Pfizer's 'Lightspeed' transformation switched from monthly to twice-weekly decision meetings. The result: 221 days from First-in-Human to approval. They are now applying that model to other high-priority programmes including Paxlovid.
A major pharmaceutical company I am aware of transferred 70% of decisions from governance bodies directly to the asset teams closest to the data. Senior leaders shifted from hands-on decision-makers to visionaries and coaches. The result was a complete transformation in decision speed and team accountability — without sacrificing governance quality.
The Agile Governance Playbook
Based on transformation work I have led and the patterns visible across the industry, the organisations closing the decision latency gap share five practices:
- Empower asset teams. Move 70% of decisions to the teams closest to the data. Reserve governance committees for truly strategic choices requiring senior input — not operational updates that teams are better positioned to resolve themselves.
- Weekly decision windows. Leading companies meet bi-weekly or weekly, not monthly. Some allow resource reallocation as frequently as every week. The calendar should serve the science, not constrain it.
- Dynamic expert committees. Assemble decision groups based on the expertise the specific decision requires. A gene therapy programme needs different expertise than a small molecule programme — and rigid standing committees rarely reflect that reality.
- Integrated reviews. Combine scientific, technical, and business reviews into single discussions rather than sequential approval gates. Sequential gates multiply latency. Integrated reviews compress it.
- Leverage digital tools. Real-time portfolio visibility reduces the need for scheduled review meetings by keeping decision-makers continuously informed. AI analytics can flag risk and status changes as they happen, not when the next committee convenes.
The Quality Paradox
The immediate pushback to faster governance is almost always the same: "But we need time for quality decisions."
This is a false choice.
A decision that takes six weeks because a committee met once for two hours is not more thoughtful than a decision made in six days across three focused sessions with the right people in the room. The organisations that have made this shift prove it repeatedly: faster decisions combined with structured decision quality frameworks produce better outcomes, not worse ones.
Before investing in AI copilots, parallel experimentation, or digital R&D platforms, fix the bottleneck costing you months right now: decision latency. Monitor your Decision Latency Index. Benchmark against best-in-class. Then transform your governance model. The patients waiting for your therapies do not care about your meeting schedules. They care about speed to market.
The good news is that this is one of the most tractable problems in pharma R&D. It does not require new science, new technology, or new people. It requires the organisational courage to redesign how decisions are made — and a governance model built for the speed that drug development actually demands.